Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Harvard Business School

Last Updated: December 3, 2022

Details for Patent: 8,613,950

✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions

Which drugs does patent 8,613,950 protect, and when does it expire?

Patent 8,613,950 protects STAXYN and is included in one NDA.

This patent has fifty-four patent family members in thirty-eight countries.

Summary for Patent: 8,613,950
Title:Pharmaceutical forms with improved pharmacokinetic properties
Abstract: The present application relates to novel drug formulations of vardenafil which dissolve rapidly in the mouth and lead to increased bioavailability and to a plateau-like plasma concentration profile, and to processes for their preparation.
Inventor(s): Serno; Peter (Gladbach, DE), Heinig; Roland (Wuppertal, DE), Pauli; Kerstin (Dortmund, DE), Hayauchi; Yutaka (Leverkusen, DE)
Assignee: Bayer Intellectual Property GmbH (Monheim, DE)
Application Number:11/885,019
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 8,613,950
Patent Claim Types:
see list of patent claims
Formulation; Compound; Dosage form; Device;

Drugs Protected by US Patent 8,613,950

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Bayer Hlthcare STAXYN vardenafil hydrochloride TABLET, ORALLY DISINTEGRATING;ORAL 200179-001 Jun 17, 2010 DISCN Yes No See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 8,613,950

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Germany10 2005 009 240Mar 1, 2005
PCT Information
PCT FiledFebruary 16, 2006PCT Application Number:PCT/EP2006/001393
PCT Publication Date:September 08, 2006PCT Publication Number: WO2006/092207

International Family Members for US Patent 8,613,950

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 053552 See Plans and Pricing
Argentina 111572 See Plans and Pricing
Austria 552828 See Plans and Pricing
Australia 2006220100 See Plans and Pricing
Brazil PI0609375 See Plans and Pricing
Canada 2599617 See Plans and Pricing
China 101141950 See Plans and Pricing
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Boehringer Ingelheim
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.